MedTrace Logo

Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)

NCT02026609 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2017-04-17

No results posted yet for this study

Summary

Transjugular intrahepatic portosystemic shunt (TIPS) is the first-line therapy for patients with cirrhosis and refractory ascites. However, mental changes known as hepatic encephalopathy (HE) frequently occur after TIPS. There is no effective method to predict HE after TIPS. Oral glutamine challenge (OGC) and psychometric tests have been used to assess the risk for HE, but never in patients undergoing TIPS. Severe muscle loss may also predispose patients to HE. The aim of the present study is to assess if both the OGC and psychometric tests can accurately predict the development of overt HE after TIPS. Patients will be studied before TIPS and followed after TIPS for the development of HE. The role of muscle loss in favoring HE, as well as is possible reversibility after TIPS will also be investigated.

Conditions

  • Refractory Ascites
  • Hepatic Hydrothorax
  • Hepatic Encephalopathy
  • Cirrhosis

Interventions

OTHER

Oral glutamine challenge

Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine

OTHER

Psychometric Tests

PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)

Sponsors & Collaborators

  • Université de Montréal

    collaborator OTHER

  • University Hospital, Geneva

    collaborator OTHER

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Andres Duarte-Rojo, MD, MSc · University of Arkansas

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-01-27
Completion
2015-01-27

Countries

  • United States
  • Canada
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02026609 on ClinicalTrials.gov